Acumen Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2026, on August 12, 2026. The company held $110.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which is expected to fund operations into early 2027. Research and development expenses decreased to $27.8 million from $37.1 million in the prior year period due to lower manufacturing and clinical trial costs. The company expects to report topline results for its Phase 2 ALTITUDE-AD study of sabirnetug in late 2026 and targets an IND filing for its Enhanced Brain Delivery program lead candidate by mid-2027.

Acumen Pharmaceuticals, Inc. exercised its option under a collaboration agreement with JCR Pharmaceuticals Co. Ltd. to license and develop two enhanced brain delivery (EBD) candidates for Alzheimer’s disease treatment. The selected candidates include a bispecific antibody derived from sabirnetug and a next-generation amyloid-beta oligomer-selective antibody, ACU234. Preclinical studies in murine and non-human primate models showed antibody levels 14-40x higher in non-human primates than native antibodies at 24 hours, with favorable stability and low anemia risk. Acumen Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases.